Showing results (31-40 of 47) with videos related to
Sort By:
Pageof 5
Journal of Cancer Research and Clinical Oncology|July 12, 2011
Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trialCharles Butts, Andrew Maksymiuk, Glenwood Goss, et al.European Urology|February 11, 2014
Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance statusArun A Azad, Bernhard J Eigl, Raya Leibowitz-Amit, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 5, 2013
Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistanceXin Dong, Dong Lin, Chris Low, et al.The Prostate|September 2, 2014
A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancerArun A Azad, Raya Leibowitz-Amit, Bernhard J Eigl, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2005
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancerAnthony W Tolcher, Kim Chi, John Kuhn, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 25, 2016
A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207Paul Wheatley-Price, Quincy Chu, Maria Bonomi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 27, 2011
Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancerJanessa J Laskin, Garth Nicholas, Christopher Lee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2015
Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung CancerBarbara Melosky, Helen Anderson, Ronald L Burkes, et al.BMC Cancer|July 14, 2007
Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patientsTrevor J Pugh, Gwyn Bebb, Lorena Barclay, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2005
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancerCharles Butts, Nevin Murray, Andrew Maksymiuk, et al.Pageof 5